Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Subscribe|Follow Us On
Europe’s First CAR T Cell Trial for Amyloidosis Opens
[University College London (UCL)] Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers.
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase I Trial of Lira-cel Ovarian Cancer CAR-T Therapy
[Anixa Biosciences, Inc. (PR Newswire)] Anixa Biosciences, Inc. announced updated positive survival observations from its ongoing Phase I clinical trial of liraltagene autoleucel, or lira-cel, a follicle-stimulating hormone receptor-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.
In Vivo Reprogramming of Cytotoxic Effector CD8 T Cells via Fractalkine-Conjugated mRNA-LNPs
[Science Immunology] Scientists demonstrated that fractalkine-conjugated mRNA lipid nanoparticles can specifically target and deliver mRNA to CX3CR1+ effector CD8 T cells in vitro and in vivo.
Ikaros Degradation by Mezigdomide Reduces T-Cell Dysfunction and Improves the Efficacy of Antimyeloma T-Cell Therapies
[Blood] Using bone marrow samples from multiple myeloma patients, scientists demonstrated a reduction in dysfunctional T cell populations expressing exhaustion markers such as TIGIT, upon treatment with Mezigdomide. They demonstrated the ability of Mezigdomide to enhance survival outcomes from anti-BCMA CAR-T therapy.
Antigen Spreading Mediates Heterogeneous Solid Tumor Eradication by DNA Demethylating Agent-Programmed CAR T Cells
[Science Advances] Investigators highlighted the potent antitumor activity of low-dose decitabine-primed CAR T cells (dCAR T) in solid tumor models, a benefit previously confirmed in hematologic malignancies. dCAR T cell infusion in immunocompetent mice led to elimination of mixed tumor masses containing, without the need for prior lymphodepletion.
Dual-Antigen-Targeting T Cell Immunotherapies in MM: Circumventing Tumor Heterogeneity and Preventing Antigen Escape
[Blood] Studies with limited numbers of patients have demonstrated that CAR T-cell products with specificity for >1 antigen are effective in advanced multiple myeloma; however, at this time, none of the dual-targeting CAR T-cell products have been shown to be clearly superior to targeting BCMA alone with ciltacabtagene autoleucel.
Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis
[Advanced Science] Using multiple mouse models, scientists found that the impact of CAR-T cells on tumor growth is dose-dependent, capable of promoting, having no effect on, or inhibiting tumor growth. Combining CCL5-knockout CAR-T cells with the CCR5 inhibitor maraviroc significantly enhanced antitumor efficacy.
CAR T-Cells Targeting CD117 Effectively Eliminate Mast Cells in Preclinical Models of Advanced Systemic Mastocytosis
[Leukemia] Scientists assessed the therapeutic potential of anti-CD117 CAR T cells to target neoplastic mast cells (MCs) in systemic mastocytosis (SM). Anti-CD117-CAR T-cells lysed several SM-related human MC cell lines, MCs differentiated from SM patient-derived iPSCs, and neoplastic bone marrow cells.
RNA-Triggered Cell Killing with CRISPR-Cas12a2
[Nature] Researchers showed that Cas12a2, a recently discovered type V CRISPR nuclease, exhibits RNA-triggered DNA shredding15,16, and enables programmable and sequence-specific elimination of yeast and human cells expressing a target transcript.
Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-Cell Population with a Lack of Memory Markers
[Cancer Immunology Research] Scientists performed single-cell RNA and T cell receptor sequencing of tumor-infiltrating lymphocytes (TILs) isolated from patient tumors and their paired ex vivo expanded cell products. They found large transcriptional differences between pre- and post-expansion TILs.
Engineered CCR7 Overexpression Enhances Nodal CAR T-Cell Homing and Cytotoxicity toward B-Cell Lymphoma
[Cancer Immunology Research] Investigators showed that CAR T cells downregulated the chemokine receptor CCR7, crucial for nodal homing, during manufacturing. To improve nodal CAR T-cell trafficking, they engineered anti-CXCR5 CAR T cells, targeting mature lymphoma, with stable CCR7 expression.
Constitutive STAT3 Signaling, in Comparison with STAT5, Enhances CAR T-Cell Efficacy, and Lowers Systemic Toxicity
[Cancer Immunology Research] Scientists engineered CAR T cells to express constitutively active mutants of STAT3 and STAT5 to investigate their individual functions. Co-expression of constitutive active mutants (ca) of STAT3 and caSTAT5 markedly enhance the long-term proliferative capacity of CAR T cells, even in the absence of antigen stimulation or cytokine supplementation.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
